Back to today’s briefing

Story perspectives

Prime Medicine Launches Hopeful Cure for AAT Deficiency

3/19/2025

49 6

Summary

Story summary

Prime Medicine, Inc. is taking a groundbreaking step in the fight against Alpha-1 Antitrypsin Deficiency (AATD) by launching a preclinical program utilizing its innovative Prime Editing technology. This initiative targets the SERPINA1 gene mutation, with plans to seek clinical testing approval by mid-2026, offering hope for a potential cure for this debilitating genetic disorder impacting lung and liver health.

1 of 1

Story summary

Prime Medicine, Inc. is taking a groundbreaking step in the fight against Alpha-1 Antitrypsin Deficiency (AATD) by launching a preclinical program utilizing its innovative Prime Editing technology. This initiative targets the SERPINA1 gene mutation, with plans to seek clinical testing approval by mid-2026, offering hope for a potential cure for this debilitating genetic disorder impacting lung and liver health.